Monte Rosa Receives $50M Payment from Novartis for Phase 2 Trial Milestone
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) received a $50 million milestone payment from its partner, Novartis (NYSE:NVS), following the initiation of a Phase 2 trial for MRT-6160 in Sjögren's disease. This marks an important step in their collaboration that could be worth up to $2.1 billion if all development milestones are met. The ongoing study, fully funded by Novartis, will assess the drug’s efficacy over a year and determine optimal dosing for future Phase 3 trials. MRT-6160 has already shown promising results in earlier trials with significant reductions in VAV1 protein levels and inflammation markers without serious side effects. Despite these developments, Monte Rosa continues to report growing losses due to rising research and administrative costs. The company’s cash reserves are expected to last until 2029 but depend on continued milestone payments from Novartis.
Topics: clinical trial drug development partnership milestone payment